Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
22.37
-0.69 (-2.99%)
At close: Mar 3, 2025, 4:00 PM
22.40
+0.03 (0.13%)
Pre-market: Mar 4, 2025, 7:20 AM EST
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $55.31M in the quarter ending September 30, 2024, with 96.58% growth. This brings the company's revenue in the last twelve months to $157.37M, up 21.65% year-over-year. In the year 2023, Rigel Pharmaceuticals had annual revenue of $115.78M with 0.03% growth.
Revenue (ttm)
$157.37M
Revenue Growth
+21.65%
P/S Ratio
2.49
Revenue / Employee
$1,070,571
Employees
147
Market Cap
394.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 115.78M | 40.00K | 0.03% |
Dec 31, 2022 | 115.74M | -22.99M | -16.57% |
Dec 31, 2021 | 138.74M | 30.12M | 27.72% |
Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
Dec 31, 2019 | 59.29M | 14.78M | 33.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RIGL News
- 7 days ago - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update - PRNewsWire
- 5 weeks ago - Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - PRNewsWire
- 7 weeks ago - Rigel Provides Business Update and 2025 Outlook - PRNewsWire
- 7 weeks ago - Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PRNewsWire
- 7 weeks ago - Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents - Seeking Alpha
- 3 months ago - Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - PRNewsWire